#### **UNITED STATES** SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

#### FORM 8-K

CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 9, 2023

# G1 THERAPEUTICS, INC. (Exact name of registrant as specified in its charter)

	Delaware (State or other jurisdiction of incorporation)	001-38096 (Commission File Number)	26-3648180 (IRS Employer Identification No.)			
700 Park Offices Drive Suite 200 Research Triangle Park, NC (Address of principal executive offices)						
	Registrant's telephone number, including area code: (919) 213-9835					
Check	Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:					
	Written communications pursuant to Rule 425 under the Securities	Act (17 CFR 230.425)				

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol	Name of each exchange on which registered	
Common stock, \$0.0001 par value	GTHX	The Nasdaq Stock Market	

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging Growth Company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  $\square$ 

#### Item 7.01 Regulation FD Disclosure.

Attached to this Current Report on Form 8-K as Exhibit 99.1 is a presentation (the "Presentation"), which is incorporated herein by reference. The Company will use the Presentation in various meetings with securities analysts, investors, and others beginning January 9, 2023.

Pursuant to General Instruction B.2 of Current Report on Form 8-K, the information contained in, or incorporated into, Item 7.01, including the Presentation attached hereto as Exhibit 99.1, is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any registration statement or other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference to such filing.

#### Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No. Description 99.1

104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

#### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

#### G1 THERAPEUTICS, INC.

/s/ James Stillman Hanson James Stillman Hanson General Counsel

Date: January 9, 2023



### 41st Annual J.P. Morgan Healthcare Conference

Wednesday January 11, 1:30 PM PT

Advancing our Mission to Improve the Lives of those Affected by Cancer

### Forward-Looking Statements

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forwardlooking statements in this presentation include, but are not limited to, those relating to expectations for the commercial success of COSELA® (trilaciclib), our ability to accelerate adoption of COSELA in the treatment of small cell lung cancer, the therapeutic potential of trilaciclib in the treatment of colorectal cancer, triple negative breast cancer, and other cancers, our ability to generate data to maximize trilaciclib's applicability to future treatment paradigms, and our reliance on partners to globally develop and commercial licensed products. In addition, COSELA may fail to achieve the degree of market acceptance for commercial success, and the impact of pandemics such as COVID-19 (coronavirus), are based on our expectations and assumptions as of the date of this presentation. Each of these forward-looking statements involves risks and uncertainties. Factors that may cause our actual results to differ from those expressed or implied in the forward-looking statements in this presentation are discussed in our filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" sections contained therein and include, but are not limited to, our ability to successfully commercialize COSELA; our ability to complete clinical trials for, obtain approvals for and commercialize additional indications of COSELA and any of our product candidates other than COSELA; our initial success in clinical trials may not be indicative of results obtained when these trials are completed or in later stage trials; the inherent uncertainties associated with developing new products or technologies and operating as a commercial-stage company; and market conditions. Lerociclib is not approved by the FDA. Except as required by law, we assume no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

G1Therapeutics® and G1Therapeutics logo and COSELA® and COSELA logo are trademarks of G1 Therapeutics, Inc. ©2022 G1 Therapeutics, Inc.



### Evolution of G1: Building Upon Unique Product - Trilaciclib



Maximizing the dual benefits of trilaciclib with the potential to improve overall survival




# 2023: Establishing the Foundation for Near-Term Growth

Two meaningful near-term commercial opportunities	<ul> <li>1L CRC: February 2023 pivotal / 4Q 2023 PFS data; large opportunity with potential launch in early 2024</li> <li>1L TNBC: 2H 2023 pivotal readout; high confidence based on Ph. 2 data with potential launch in late 2024</li> </ul>
Ph2 readouts to inform additional pivotal studies	<ul> <li>2L / 3L TNBC (ADC): Initial efficacy data expected in 2Q 2023; preliminary data suggests reduced AEs</li> <li>Neoadjuvant TNBC (MOA): Pathologic CR data expected in 2Q 2023; initial data supported immune MOA</li> <li>1L mUC: Longer term anti-tumor efficacy endpoints, including PFS and DOR, expected in mid-2023</li> </ul>
Considerable growth potential remaining in ES-SCLC market	COSELA trial usage at key accounts has been encouraging but limited depth remains a challenge     Refocusing commercial resources on largest opportunities to drive increased depth
Positioning company for global expansion and long-term growth	<ul> <li>Planning to secure a partner for global expansion (beyond U.S. and China) in 2023</li> <li>Evaluating additional late-stage studies for 2H 2023 initiation; pursuing research next generation products</li> <li>Strengthened financial position heading into data-rich period with \$52.4M net proceeds from 4Q 2022 offering</li> </ul>



Note: CRC: Colorectal cancer; TNBC: Triple negative breast cancer; MOA: Mechanism of Action; mUC: Metastatic urothelial carcinoma; PFS: Progression free survival; CR: Complete response; DOR: Duration of response

# Myeloprotection: Protecting Bone Marrow from Cytotoxic Damage



#### **Potential Benefits of Myeloprotection**


- Improves patients' QoL
- Decreases rescue interventions, hospitalizations, associated costs
- Protects immune system function from damage by cytotoxic therapy
- Enables patients to tolerate greater exposure to cytotoxic therapy

Trilaciclib helps protect HSPCs and myeloid and lymphoid cell lineages from damage caused by cytotoxic therapy - providing multiple potential benefits



Hematopoietic tree adapted from 'Hematopoietic Tree, Plasma Cell', National Cancer Institute Visuals Online: https://visualsonline.cancer.gov/details.cfm?imageid=7177 1. Weiss J, et al. Ann Oncol. 2019 Oct; 30(10): 1613–1621. 2. He S, et al. Sci Transl Med. 2017;9:eaal3986. 3. Bisi JE, et al. Mol Cancer Ther. 2016;15:783-93.

### Potential to Enhance Anti-Tumor Immunity




Trilaciclib enhances multiple immunological processes – providing synergistic benefit in combination with chemotherapy, ADCs and checkpoint inhibitors



Tools 1 Byoring MJ, etc. 1 CR64 in the control of t

### Marketed Product Providing Pipeline-in-a-Molecule





COSELA is marketed in the U.S. by G1 and conditionally approved in Greater China to be marketed by our partner, Simcere conditionally approved in Greater China to be marketed by our partner, Simcere. Trilacicibl is an investigational drug in all other indications and its safety and efficacy has only been established in Es-ScLC

1L. CRC data readout in 10 2023 expected to include results for myeloprotection and early indicators for anti-tumor efficacy; Initial PFS expected 4Q 2023

1L. TNBC data readout in 10 2023 expected to include interim results for Overall Survival (OS); event-driven interim OS analysis to be


For Investor Use Conducted by its DMC in 4Q 2023



# Phase 3 Data in 2023: CRC and TNBC

### 1L CRC: Significant Near-Term Opportunity

U.S. CRC Patient Population (2021)1



#### Chemotherapy remains primary backbone for mCRC

- Majority of patients have microsatellite stable (MSS) tumors
- ~47k annual first-line drug-treated MSS CRC patients in the U.S

#### ■ FOLFOXIRI only used in ~10% to ~20% of U.S. patients

- Most efficacious regimen but currently limited due to toxicities
- Typically reserved for younger healthier patients with larger tumors
- Significant potential to expand FOLFOXIRI usage
  - Meaningfully reducing adverse events would address critical hurdle
  - Further increasing efficacy would be transformative advancement

Trilaciclib has potential to optimize the tolerability and efficacy of FOLFOXIRI and meaningfully improve care for patients living with metastatic CRC



. Estimates from Kantar Health CancerMPact Patient Metrics, and internal research and analysis

# FOLFOXIRI: Most Efficacious; Tolerability Issues Limit Use

	FOLFOXIRI + bevacizumab <sup>1</sup> (N = 846)	Doublet + bevacizumab¹ (N = 851)	P Value <sup>1</sup>
Efficacy Data:			
ORR	64.5%	53.6%	<.001
Median PFS	12.2	9.9	<.001
Median OS	28.9	24.5	<.001
Neutropenia <sup>2</sup>	45.8%	21.5%	<.001
Neutropenia <sup>2</sup> Diarrhea	45.8% 17.8%	21.5% 8.4%	<.001 <.001
1.500	100000000000000000000000000000000000000	07/05/20/05/0	
Diarrhea	17.8%	8.4%	<.001
Diarrhea Arterial Hypertension	17.8% 7.8%	8.4% 7.8%	<.001 .938
Diarrhea Arterial Hypertension Febrile Neutropenia	17.8% 7.8% 6.3%	8.4% 7.8% 3.7%	<.001 .938 .019



Meta-analysis: Cremolini C, et al. Individual Patient Data Meta-Analysis of FOLFOXIRI Plus Bevacizumab Versus Doublets Plus Bevacizumab as Initial Therapy of Unresectable Metastatic Colorectal Canons J. I (în Incent) 2079.38:3314.33236.

Note: Grade 4 neutropenia -19% for FOLFOXIRI + bevacizumab and -7% for doublet + bevacizumab based on TRIBE2 results (Cremolini, et al. Upfront FOLFOXIRI plus bevacizumab and reintroductio after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre,

# Ongoing Ph3 First-Line CRC Pivotal Trial: PRESERVE 1

Evaluating trilaciclib prior to FOLFOXIRI/bevacizumab in 1L CRC (pMMR/MSS) patients



PRIMARY ENDPOINT:
Myeloprotection: SN during Induction
& DSN Cycles 1-4

SECONDARY ENDPOINTS: PRO, PFS, OS

ENROLLMENT COMPLETED: 326 participants

Myeloprotection results in February 2023; Initial PFS expected 4Q 2023

Positive myeloprotection results enables sNDA submission; initial PFS data likely available prior to any future launch



# Three Key Areas for 1L CRC February Data Readout




February data readout will clarify the overall opportunity in 1L CRC



### Potential to Become Standard of Care in 1L CRC

#### First-Line CRC Treated Patients (MSS)




Trilaciclib could optimize the most efficacious treatment regimen with potential to improve tolerability and increase survival



### 1L TNBC: Important Area of High Unmet Need

U.S. TNBC Patient Population (2021)1



#### TNBC tumors are aggressive and difficult to treat

- Categorized by lack of HR expression and HER2 gene amplification
- Trilaciclib demonstrated robust survival benefit with chemo in Ph2

#### Chemo +/- targeted therapy remains first-line TNBC SoC

- ~9k annual first-line drug treated TNBC patients in the U.S.
- Targeted therapies only demonstrated benefit in subpopulations


#### Trilaciclib demonstrated broad benefit in Randomized Phase 2

- Benefit observed across PD-(L)1+ and PD-(L)1- subpopulations
- Patients receive 4 vials of trilaciclib for each 3-week cycle

Potential to meaningfully increase overall survival across 1L TNBC subpopulations



### Observed Robust OS Improvement in mTNBC Foundational Data for PRESERVE 2: Completed Randomized Phase 2 Trial



#### Fast Track Designation granted as a result of these data (July 2021)



# Overall Survival Most Significant Effect in mTNBC Study Randomized Phase 2: Combination with Chemotherapy

Greatest Effect + Least Effect P-Values 0.001 0.108 0.235 100% 20 Response Rate 75% 9.0 10 50% 25% 0 0% Overall Survival Progression Free Survival Best Overall Response Group 2 + Group 3 (trilaciclib arms)

Trilaciclib demonstrated the most robust effect on OS, consistent with its observed immunomodulatory effects



. O'Shaughnessy et al., 2020 San Antonio Breast Cancer Symposium (SABCS), Poster #PD1-06. Note: primary endpoints relating to reduction in severe neutropenia not achieved in this 2. Patients randomized to receive genricarbo chemotherapy only (Group 1) or genricarbo plus one of two dosing schedules of trilacicilib : trilacicilib administered on the day of chemotherapy (Group 2) or telepriciph administered the day order on and the day of chemotherapy (Group 2) or telepriciph administered the day order to and the day of chemotherapy (Group 2) or telepriciph administered the day order to another day of chemotherapy (Group 2) or telepriciph administered the day order to another day of chemotherapy (Group 2) or telepriciph administered the day order to another day of the day o

# OS Improvement Observed, Regardless of PD-L1 Status

### Overall Survival for PD-L1 Positive Tumors<sup>1</sup> Median OS (95% CI), Months Hazard Ratio (95% CI) Group 1: (gem/carbo) 10.5 (6.3 – 18.8)

32

**32.7** (17.7 – NR)

**0.34** (0.2 – 0.7)

Overall Survival for PD-L1 Negative Tumors <sup>1</sup>				
Treatment Group <sup>2</sup>	Patients	Median OS (95% CI), Months	Hazard Ratio (95% CI)	P Value
Group 1: (gem/carbo)	10	13.9 (12.6 – NR)	-	-
Group 2 and 3: (gem/carbo + trilaciclib)	26	17.8 (13.1 – NR)	0.48 (0.2 – 1.2)	0.093

Overall Survival improvement was observed regardless of tumor PD-L1 status (greater effect in PD-L1 positive tumors)



Group 2 and 3: (gem/carbo + trilaciclib)

0.004

## Ongoing First-Line TNBC Ph3 Pivotal Trial: PRESERVE 2

Initial positive evidence of efficacy across subsets and line of treatment in Phase 2 trial<sup>1</sup> Evaluating 1L patients (PD-L1 positive and negative patients)



PRIMARY ENDPOINT: Overall Survival

SECONDARY ENDPOINTS: PFS, ORR, PRO,

myeloprotection measures

ENROLLMENT COMPLETE:

187 participants

Interim OS analysis at 70% of events expected in 2H 2023

Pivotal study evaluating trilaciclib in mTNBC building upon robust OS benefit observed in prior randomized Phase 2 study



O'Shaughnessy et al., 2020 San Antonio Breast Cancer Symposium (SABCS), Poster #PD1-06



Ongoing Phase 2 Studies and Future Development

### Three Ongoing Phase 2 Proof of Concept Studies

**Proof of Concept Study** 

Key Goals of Study Related to Trilaciclib

2L / 3L TNBC (Phase 2)

- $1. \ \ \text{Evaluate} \ \underline{\text{myeloprotection benefits with an ADC}} \ (\text{sacituzumab govitecan in this study})^1$
- 2. Determine whether increased cytotoxic exposure and potential synergy increases PFS / OS

Neoadjuvant TNBC (Phase 2)

- 1. Clinically **confirm mechanistic effects** that appear to be driving increased immunomodulation<sup>2</sup>
- 2. Evaluate if there is an anti-tumor efficacy signal in early stage TNBC patients

1L Bladder Cancer (Phase 2)

- 1. Demonstrate ability to increase survival across additional tumors<sup>3</sup>
- 2. Evaluate if synergistic benefits with a CPI observed preclinically is translatable to humans



Preliminary myeloprotection data for first 18 patients announced in press release November 11, 2022
Preliminary change in CB8+ T-cell / Trag ratio announced in press release on December 7, 2022
Initial data including ORR endpoints announced in press release January 4, 2023

## Phase 2 ADC Combination Study: 2L/3L Metastatic TNBC

Evaluate synergistic combo potential of trilaciclib and sacituzumab govitecan-hziy, each of which have individually demonstrated clinically meaningful OS improvements in TNBC



PRIMARY ENDPOINT: PFS

SECONDARY ENDPOINTS: ORR, CBR, OS, myeloprotection measures

TARGET ENROLLMENT: Up to 40 participants

PATIENTS TREATED UNTIL PROGRESSION

PFS data expected 2Q 2023

Strong belief in clinical rationale underlying this combination; data generated will be instructive in evaluating future ADC combination possibilities



### Initial Results from Phase 2 ADC Combination Study

Adverse events in patients receiving trilaciclib in combination with sacituzumab govitecan-hziy (n=18)

Summary of TEAEs (≥ 15% of patients) in patients receiving trilaciclib in combination with sacituzumab govitecan-hziy Adverse Event
Fatigue
Nausea
Constipation
Diarrhea
Headache
Neutropenia
Decreased Appetite
Leukopenia
Abdominal Pain Upper
Alopecia Summary of other relevant TEAEs in patients receiving trilaciclib in combination with sacituzumab govitecan-hziy Adverse Event Any Grade Grade 3-4 Anemia Febrile Neutropenia Thrombocytopenia

Adverse events in patients receiving sacituzumab govitecan-hziy (n=258)

Adverse Event	Any Grade	Grade 3-4
Fatigue	52%	4%
Nausea	62%	<4%
Constipation	37%	<1%
Diarrhea	65%	11%
Headache	18%	1%
Neutropenia	64%	52%
Decreased Appetite	28%	2%
Leukopenia	17%	10%
Abdominal Pain Upper	21%	3%
Alopecia	47%	0%
Summary of oth	47% ner relevant treatment-re receiving sacituzumab	lated adverse events
Adverse Event	Any Grade	Grade 3-4
	34%	8%
Anemia		
Anemia Febrile neutropenia	6%	6%

Preliminary data highlight potential to reduce adverse events, including on target effects on neutropenia and diarrhea



Note: TEAE = Treatment emergent adverse event

1. Adapted from Bardia A, et al. Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer. N Engl J Med 2021;384:1529-41. DOI: 10.1056/NEJMoa2028485. Table S1

2. Adapted from Bardia A, et al. Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer. N Engl J Med 2021;384:1529-41. DOI: 10.1056/NEJMoa2028485. Table S1

### Phase 2 Neoadjuvant TNBC: Mechanism of Action (MOA) Study

Confirm immune-based properties of trilaciclib and its potential role in increasing the anti-tumor efficacy of chemotherapy with and without a checkpoint inhibitor



PRIMARY ENDPOINT: Immune-based MOA

SECONDARY ENDPOINTS: pCR, immune response and profiling measures

ENROLLMENT COMPLETED: 24 patients


pCR data expected 2Q 2023

Data will inform design of future additional studies across multiple tumor types and treatment combinations



### Initial Results from Phase 2 MOA Study in Neoadjuvant TNBC

Change in CD8+ T-cell / Treg Ratio in Tumor Tissue Over 7 Days Post Trilaciclib Monotherapy (N=23); Per Patient (A) and Overall (B)



Initial data suggests favorable alterations in tumor microenvironment following single administration of trilaciclib



a Patient had TNBC with neuroendocrine features
b Calculated using the Wilcoxon signed-rank test
CD8: Cluster of differentiation 8; Q: Quarter; Treg: regulatory T cell.

### Phase 2 Bladder (mUC) Study: PRESERVE 3

Building on strong rationale for trilaciclib in a known immunogenic tumor; focused on ability to increase PFS in checkpoint combination



PRIMARY ENDPOINT: PFS

SECONDARY ENDPOINTS: ORR, DCR, DOR, OS, myeloprotection measures

ENROLLMENT COMPLETED: 92 participants

PATIENTS TREATED UNTIL PROGRESSION

PFS and duration of response expected mid-2023

Phase 2 study will provide meaningful data to help define future combination studies




### Initial Results from Phase 2 Bladder Study

- Confirmed objective response rate (ORR) per RECIST v1.1 was comparable between arms
  - ORR was 40.0% (n=18/45) and 46.7% (n=21/45) in the trilaciclib and control arms, respectively
  - Longer-term follow-up required to characterize additional anti-tumor endpoints:
    - Median duration of confirmed objective response (DOR)
    - PFS (primary endpoint of the study)
- Safety and tolerability profile is generally consistent with expectations for patients treated with gemcitabine plus cisplatin/carboplatin and avelumab maintenance in 1L mUC
  - DMC has recommended the study continue as planned



### Potentially Ideal Treatment Settings for Future Studies



Focused on ideal treatment settings where trilaciclib has unique ability to further improve survival in combination with important leading and emerging treatments






COSELA® (trilaciclib) in ES-SCLC

### COSELA

### COSELA in ES-SCLC: Opportunity to Impact Many Lives

U.S. ES-SCLC Patient Population (2022)



- Demonstrated reductions in multiple myelosuppressive consequences and hematologic adverse events
  - Across multiple randomized SCLC studies and Real-World Evidence studies
- ES-SCLC patients predominantly treated with highly myelosuppressive chemo regimens
  - Opportunity for innovation given aggressiveness of disease (1L median OS ~1 year<sup>4</sup>)
  - Standard treatment includes ~4 cycles of chemo
- Strong reimbursement, majority in Medicare


COSELA can significantly improve the chemotherapeutic experience and improve the lives of patients with ES-SCLC





# Eight Percent (8%) Vial Volume Growth in 4Q22





5-10% current penetration; considerable growth potential remaining in ES-SCLC market



#### **COSELA** trilaciclib for inject

# Progress with 4Q22 Account Depth and Breadth Top 100 Organizations



- 69 of Top 100 US customer organizations have trialed COSELA launch to date (8 new in 4Q22)
  - >30% of US market potential in these 69 Top 100 organizations
- Depth continues to be the challenge
  - 14% depth in Top 100 organizations
  - 17% depth across all organizations with utilization

Continued breadth of trial, especially in Community, with opportunity to grow depth





### Response to Challenges in ES-SCLC Market

#### **Challenges to Building Depth**

- · Relatively rare tumor type
  - Variable incidence across territories
  - Not top of mind when even large clinics have only one or two eligible patients at a time
  - Reluctance to make systematic changes in process for small number of patients
- Short duration of chemotherapy treatment
  - <90-day duration of chemotherapy for most patients means no continuing business quarter to quarter
- Palliative care focus
  - Many physicians prefer to dose reduce or delay given poor survival prognosis
  - Academic organizations more focused on implementing change for survival outcomes

#### **Actions Being Taken**

- Community Clinic Focus
  - Multiple volume-based contracts in place for Q1 (more anticipated)
  - Patient Reported Outcome focus of promotion
  - Specialist EMR team to support clinic adoption
- Optimizing field deployment for community clinics
  - 29 territories with highest opportunity
  - Virtual hybrid sales representative augmenting enhanced digital marketing for unstaffed territories
- Medically-led model for academic centers
  - Scientific engagement with academic lung experts

Refocusing commercial resources on largest opportunities to drive increased depth





## Significantly Larger Commercial Opportunity in 1L CRC

**Comparing Opportunity** 

1L/2L ES-SCLC	Characteristics	1L CRC
~20K addressable patients	Addressable Market	~47K addressable patients
• ~4 cycles over ~3 months (~24 vials of trilaciclib)	Duration of Therapy	• ~12-24 cycles over ~6-12 months (~48-96 vials of trilaciclib)
Smaller patient population skewed to Medicare	Patient Mix	Higher patient frequency; even mix of Commercial and Medicare
Typically, poorer prognosis at diagnosis Trilaciclib primarily supportive care in this setting	Therapeutic Goals	Better prognosis facilitates more aggressive therapeutic approaches     Trilaciclib may enable a more efficacious regimen and increase OS

Broader use in 1L CRC may help increase awareness and adoption of trilaciclib in ES-SCLC patients





### **Efficiently Managing Capital**

### Potential for Meaningful Incremental Value from Out-Licensed Assets

#### \$123M in cash, cash equivalents, and marketable securities as of Sept. 30, 2022

· Additional \$25M of debt facility currently available but not yet drawn


Additional \$52.4M in net proceeds from 4Q22 public offering

#### Additional potential proceeds from existing license agreements



Potential for \$461 million in milestone payments (as of 12/31/22) plus royalties





### **G1** Therapeutics

#### Unique Investment Opportunity Poised for Near-Term Growth



#### Near-Term Commercial Opportunities

- 1L CRC: Pivotal data February 2023; potential early 2024 lauch
- 1L TNBC: Interim OS 2H 2023; given fast-track designation with potential 2024 launch



#### Multiple Phase 2 Data Readouts

- Additional data from three Ph2 studies in 2023
- Will inform additional latestage studies



#### Growth Potential in Marketed Indication

- Considerable growth potential remaining in ES-SCLC market
- Focusing on increasing depth at top accounts



#### **Global Expansion**

- Planning to secure a partner for global expansion in 2023
- Pursuing research on next generation products

